DCP as a biomarker for TACE efficacy in hepatocellular carcinoma
IntroductionPrimary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.MethodsWe retrospectively analyzed 90 PHC patients treated with TACE....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1560210/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849245510587645952 |
|---|---|
| author | Hui Xie Youwei Li Jie Yang Yuwei Tan Jin Xu Xiao Yang |
| author_facet | Hui Xie Youwei Li Jie Yang Yuwei Tan Jin Xu Xiao Yang |
| author_sort | Hui Xie |
| collection | DOAJ |
| description | IntroductionPrimary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.MethodsWe retrospectively analyzed 90 PHC patients treated with TACE. Serum DCP levels were measured pre-treatment and at 1, 4, and 8 weeks post-treatment. Treatment response was evaluated using mRECIST criteria.ResultsLow DCP patients (≤40 mAU/mL) showed significantly higher response rates (53.3%) compared to high DCP (>300 mAU/mL, 30.0%, p<0.05). The hazard ratio for treatment failure was 1.62 (95% CI: 1.09–2.23, p<0.01) per unit increase in log-transformed DCP. Median overall survival was 24.5 months for low DCP versus 12.6 months for high DCP patients (log-rank p<0.001).DiscussionDCP serves as a robust biomarker for predicting TACE efficacy, enabling personalized treatment strategies in PHC management. |
| format | Article |
| id | doaj-art-448bda72ffcc4a09beca2cdda23346c6 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-448bda72ffcc4a09beca2cdda23346c62025-08-20T03:58:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.15602101560210DCP as a biomarker for TACE efficacy in hepatocellular carcinomaHui XieYouwei LiJie YangYuwei TanJin XuXiao YangIntroductionPrimary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.MethodsWe retrospectively analyzed 90 PHC patients treated with TACE. Serum DCP levels were measured pre-treatment and at 1, 4, and 8 weeks post-treatment. Treatment response was evaluated using mRECIST criteria.ResultsLow DCP patients (≤40 mAU/mL) showed significantly higher response rates (53.3%) compared to high DCP (>300 mAU/mL, 30.0%, p<0.05). The hazard ratio for treatment failure was 1.62 (95% CI: 1.09–2.23, p<0.01) per unit increase in log-transformed DCP. Median overall survival was 24.5 months for low DCP versus 12.6 months for high DCP patients (log-rank p<0.001).DiscussionDCP serves as a robust biomarker for predicting TACE efficacy, enabling personalized treatment strategies in PHC management.https://www.frontiersin.org/articles/10.3389/fonc.2025.1560210/fulldes-gamma-carboxyprothrombintransarterial chemoembolizationhepatocellular carcinomatreatment responsebiomarker |
| spellingShingle | Hui Xie Youwei Li Jie Yang Yuwei Tan Jin Xu Xiao Yang DCP as a biomarker for TACE efficacy in hepatocellular carcinoma Frontiers in Oncology des-gamma-carboxyprothrombin transarterial chemoembolization hepatocellular carcinoma treatment response biomarker |
| title | DCP as a biomarker for TACE efficacy in hepatocellular carcinoma |
| title_full | DCP as a biomarker for TACE efficacy in hepatocellular carcinoma |
| title_fullStr | DCP as a biomarker for TACE efficacy in hepatocellular carcinoma |
| title_full_unstemmed | DCP as a biomarker for TACE efficacy in hepatocellular carcinoma |
| title_short | DCP as a biomarker for TACE efficacy in hepatocellular carcinoma |
| title_sort | dcp as a biomarker for tace efficacy in hepatocellular carcinoma |
| topic | des-gamma-carboxyprothrombin transarterial chemoembolization hepatocellular carcinoma treatment response biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1560210/full |
| work_keys_str_mv | AT huixie dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma AT youweili dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma AT jieyang dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma AT yuweitan dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma AT jinxu dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma AT xiaoyang dcpasabiomarkerfortaceefficacyinhepatocellularcarcinoma |